The predominant DNA-based vaccines for prostate cancer are primarily designed to encode proteins such as Prostatic Acid Phosphatase (PAP), Prostate-Specific Membrane Antigen (PSMA), Prostate-Specific Antigen (PSA), and Androgen Receptor (AR), among others [52]. Here, FOLH1 is linked to prostate carcinoma.